- Home
- Automated
- List of product information
- ROCKLATAN OPHTHALMIC SOLUTION, 0.02% W/V / 0.005% W/V [SIN16818P]
ROCKLATAN OPHTHALMIC SOLUTION, 0.02% W/V / 0.005% W/V [SIN16818P]
Active ingredients: ROCKLATAN OPHTHALMIC SOLUTION, 0.02% W/V / 0.005% W/V
Last updated 26 October 2025
Product Info
ROCKLATAN OPHTHALMIC SOLUTION, 0.02% W/V / 0.005% W/V
[SIN16818P]
Product information
Active Ingredient and Strength | LATANOPROST - 0.005% W/V |
Dosage Form | SOLUTION, STERILE |
Manufacturer and Country | AERIE PHARMACEUTICALS IRELAND, LIMITED - IRELAND |
Registration Number | SIN16818P |
Licence Holder | SANTEN PHARMACEUTICAL ASIA PTE. LTD. |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | S01EE51 |
1. INDICATIONS AND USAGE
ROCKLATAN (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% is a fixed dose combination of a Rho kinase inhibitor and a prostaglandin F2α analogue indicated for the reduction of elevated intraocular pressure (IOP) in patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin F2α analogue or Rho kinase inhibitor provides insufficient IOP reduction.
2. DOSAGE AND ADMINISTRATION
The recommended dosage is one drop in the affected eye(s) once daily in the evening. If one dose is missed, treatment should continue with the next dose in the evening. The dosage of ROCKLATAN should not exceed once daily.
ROCKLATAN may be used concomitantly with other topical ophthalmic drug products to lower IOP.
If more than one topical ophthalmic drug is being used, the drugs should be administered at least five (5) minutes apart.
Due to netarsudil’s vasodilating properties, other eye drops should be administered before latanoprost + netarsudil. Eye ointments should be administered last.
4. CONTRAINDICATIONS
Hypersensitivity to the active substance(s) or to any of the excipients.